標(biāo)題: Titlebook: Development of Antibody-Based Therapeutics; Translational Consid Mohammad A. Tabrizi,Gadi G. Bornstein,Scott L. Kla Book 2018Latest edition [打印本頁] 作者: 債權(quán)人 時間: 2025-3-21 19:36
書目名稱Development of Antibody-Based Therapeutics影響因子(影響力)
書目名稱Development of Antibody-Based Therapeutics影響因子(影響力)學(xué)科排名
書目名稱Development of Antibody-Based Therapeutics網(wǎng)絡(luò)公開度
書目名稱Development of Antibody-Based Therapeutics網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Development of Antibody-Based Therapeutics被引頻次
書目名稱Development of Antibody-Based Therapeutics被引頻次學(xué)科排名
書目名稱Development of Antibody-Based Therapeutics年度引用
書目名稱Development of Antibody-Based Therapeutics年度引用學(xué)科排名
書目名稱Development of Antibody-Based Therapeutics讀者反饋
書目名稱Development of Antibody-Based Therapeutics讀者反饋學(xué)科排名
作者: Connotation 時間: 2025-3-21 21:56
https://doi.org/10.1007/978-3-658-27904-2erations, underlying pharmacology and pathophysiology, as well as integration of key translational considerations can accelerate drug development processes, ultimately benefiting patients in need of such therapies. In the previous edition of this book (First Edition), translational considerations fo作者: 合法 時間: 2025-3-22 04:04 作者: ineluctable 時間: 2025-3-22 08:17
Translational Considerations and Challenges: An Overview,erations, underlying pharmacology and pathophysiology, as well as integration of key translational considerations can accelerate drug development processes, ultimately benefiting patients in need of such therapies. In the previous edition of this book (First Edition), translational considerations fo作者: 貪婪的人 時間: 2025-3-22 09:33
Considerations for Construct and Affinity Design Goals, in establishing affinity design goals. Selection of the adequate affinity for a functional biologic construct should allow achievement of the maximum therapeutic benefit at a dose associated with a manageable cost of goods. This chapter will further expand on the topics discussed previously (Develo作者: Salivary-Gland 時間: 2025-3-22 15:18
Correction to: Considerations for Construct and Affinity Design Goals,作者: Salivary-Gland 時間: 2025-3-22 17:20
Introduction, topics relevant for development of antibody-based therapeutics, this Second Edition will provide in-depth coverage of the key topics related to development of targeted therapeutics with key focus on the recent developments in the field. Recent advances span development of targeted modalities in exc作者: BURSA 時間: 2025-3-22 23:28
Translational Considerations and Challenges: An Overview,ditions such as psoriasis and cancer. This high number of approvals followed the previous record number of approvals of ten monoclonal antibodies in 2015. Such high approval rate for biologics is a testament to advances in antibody technology and the unique advantage that this class of therapeutics 作者: elastic 時間: 2025-3-23 02:36 作者: 語言學(xué) 時間: 2025-3-23 06:52
Epitope Characterization and Isotype Selection,n molecular interactions are responsible for biological function(s) at a cellular level. The post-genomic era has witnessed the emergence of improved and state-of-the-art technologies to characterize structure-function relationships. The emergence of these technologies has been further facilitated b作者: 別名 時間: 2025-3-23 12:55
Biophysical Considerations for Development of Antibody-Based Therapeutics,n complexes for drug candidate optimization and the design of clinical dosing strategies. For measuring the dissociation equilibrium constants of monoclonal antibodies binding reversibly to antigens, two premier technologies are commonly used: Biacore surface plasmon resonance (SPR) and the solution作者: 薄荷醇 時間: 2025-3-23 17:06
Novel Technologies for Generation of Bispecific Constructs,odalities may offer additional advantages with respect to target engagement that may not be feasible by traditional combination therapies with single agents. Therefore, design of bispecific constructs requires particular attention to target and drug selection for successful application of this class作者: FOR 時間: 2025-3-23 21:29 作者: Minutes 時間: 2025-3-23 23:03 作者: 粗鄙的人 時間: 2025-3-24 06:07 作者: magnanimity 時間: 2025-3-24 06:39
Antibody Drug Conjugates: Translational Considerations,argeted antibodies and the high potency of small-molecule drugs with the aim of achieving durable responses in patients. As application of highly potent small-molecule drugs can be limited by their undesirable toxicity, targeted delivery of highly potent small-molecule drugs to specific cells is int作者: 狂怒 時間: 2025-3-24 11:13
Application of PK-PD Modeling and Simulation Approaches for Immuno-Oncology Drugs,ught about new challenges with critical relevance to the design of optimal dose and dosing regimens both as single-agent therapy and in combination with other cancer drugs. Since the first immune checkpoint inhibitor (ipilimumab) was introduced in clinical practice in 2011, there has been considerab作者: meretricious 時間: 2025-3-24 15:18 作者: 摘要記錄 時間: 2025-3-24 19:48 作者: 油氈 時間: 2025-3-25 01:35
risks to humans.Shows how the flow of information from lateWith a key focus on recent developments and advances in the field, this book provides in-depth coverage of topics fundamental to the development of targeted therapeutics. The expansion of targeted modalities in rapidly evolving therapeutic 作者: misshapen 時間: 2025-3-25 06:26
Book 2018Latest editionrgeted therapeutics. The expansion of targeted modalities in rapidly evolving therapeutic areas, such as immune-oncology, and developments with respect to combination therapies, novel technologies, and the therapeutic application of antibody-drug conjugates, are presented. Additionally, the book bui作者: Rankle 時間: 2025-3-25 11:17 作者: Gustatory 時間: 2025-3-25 12:58 作者: 群居動物 時間: 2025-3-25 18:23 作者: 撫慰 時間: 2025-3-25 20:38
Mengencations for high-throughput kinetic screening and epitope binning are briefly presented. Additionally, the use of cell-based affinity assays using Fluorescence Activated Cell Sorting (FACS) and KinExA is discussed for instances where purified antigens outside a cell membrane lose their native structure and/or functionality.作者: 出價 時間: 2025-3-26 00:27
te-of-the-art engineering, production, and development of recombinant protein scaffolds, development of novel bispecific modalities has witnessed an exponential growth. In this chapter the current landscape for bi- and multi-specific modalities from design, production, and developability aspects is discussed.作者: 自傳 時間: 2025-3-26 08:03
Gruppen translational topics critical for early development of this class of therapeutic. As anticipated, a successful transition of ADCs into the clinic will be highly dependent on effective translation of critical attributes governing exposure–response relationships across species.作者: bioavailability 時間: 2025-3-26 11:48
Die Entwicklung des Begriffes bis zum ALRade are ongoing. The discussions in this chapter are focused on the use of current and emergent biomarkers in the design and development of treatment combinations for cancer, with a special emphasis on emerging IO therapies.作者: AWRY 時間: 2025-3-26 16:04
Epitope Characterization and Isotype Selection,ses advances in the structural evaluation of protein-protein interactions, epitope identification relative to biological function, as well as critical considerations for drug design and intellectual property protection.作者: chuckle 時間: 2025-3-26 20:38 作者: 圓木可阻礙 時間: 2025-3-26 21:06
Novel Technologies for Generation of Bispecific Constructs,te-of-the-art engineering, production, and development of recombinant protein scaffolds, development of novel bispecific modalities has witnessed an exponential growth. In this chapter the current landscape for bi- and multi-specific modalities from design, production, and developability aspects is discussed.作者: STANT 時間: 2025-3-27 03:38 作者: intelligible 時間: 2025-3-27 07:23
Translational Biomarkers: Application in the Clinical Development of Combination Therapies,ade are ongoing. The discussions in this chapter are focused on the use of current and emergent biomarkers in the design and development of treatment combinations for cancer, with a special emphasis on emerging IO therapies.作者: semble 時間: 2025-3-27 10:25 作者: Iatrogenic 時間: 2025-3-27 15:49 作者: 菊花 時間: 2025-3-27 20:06 作者: 可用 時間: 2025-3-28 00:10 作者: 痛恨 時間: 2025-3-28 04:39
Introduction,tion of antibody-drug conjugates. We hope that this collection has successfully captured new advances relevant to the development of targeted therapeutics and will provide interested reader with an advanced knowledge of the field.作者: Flagging 時間: 2025-3-28 10:13 作者: PLAYS 時間: 2025-3-28 10:58
Application of Proof-of-Mechanism Biomarkers (POM) in Design and Development of Biologics Modalitietibody pharmacokinetics (PK) and ensuing effects on biomarkers can be effectively examined. Evaluation of exposure–response relationships in vivo can provide invaluable information with respect to antibody potency and pharmacodynamic response efficiency.作者: 惹人反感 時間: 2025-3-28 18:20
Application of PK-PD Modeling and Simulation Approaches for Immuno-Oncology Drugs, clinical response to such therapies. Hence, it is evident that application of quantitative approaches can highly enhance knowledge regarding the underlying variables important for designing effective dosing strategies in I-O therapies. This chapter focuses on the application and potential impact of PK-PD modeling on I-O therapy.作者: 顛簸下上 時間: 2025-3-28 20:19 作者: 租約 時間: 2025-3-29 02:41 作者: Tempor 時間: 2025-3-29 06:14
https://doi.org/10.1007/978-3-658-27904-2n and selection of antibody-based therapeutics. Clarity on patient-related variables, manufacturing considerations, underlying biology and pathophysiology, as well as integration of key translational variables can accelerate drug development processes, ultimately benefiting patients in need of such 作者: INCUR 時間: 2025-3-29 07:48
n molecular interactions are responsible for biological function(s) at a cellular level. The post-genomic era has witnessed the emergence of improved and state-of-the-art technologies to characterize structure-function relationships. The emergence of these technologies has been further facilitated b作者: 反叛者 時間: 2025-3-29 11:49 作者: Contend 時間: 2025-3-29 18:46
odalities may offer additional advantages with respect to target engagement that may not be feasible by traditional combination therapies with single agents. Therefore, design of bispecific constructs requires particular attention to target and drug selection for successful application of this class作者: POINT 時間: 2025-3-29 23:38
effect of most drugs arises from their interactions with various macromolecules within the organism, resulting in alterations of functional and biochemical pathways, and the concentration of drug in the proximity of the biological receptor (biophase) determines the magnitude of the observed response作者: mechanism 時間: 2025-3-30 00:25
Teiler preclinical and clinical development. Appropriate analysis of tumor growth data at the preclinical stage will aid in effective interpretation of the preclinical studies. In general, tumor growth models have a degree of intrinsic variability, so studies must be powered with an adequate number of rep作者: Pedagogy 時間: 2025-3-30 06:53
Matrizenderation during the development of antibody-based therapeutics is selection and evaluation of relevant biomarkers during early preclinical stages. Effective application of biomarkers not only lessens the time and cost associated with the drug development process, but also fosters implementation of r作者: Tartar 時間: 2025-3-30 10:58
Gruppenargeted antibodies and the high potency of small-molecule drugs with the aim of achieving durable responses in patients. As application of highly potent small-molecule drugs can be limited by their undesirable toxicity, targeted delivery of highly potent small-molecule drugs to specific cells is int作者: irritation 時間: 2025-3-30 14:00 作者: 嚴(yán)峻考驗 時間: 2025-3-30 19:28 作者: jocular 時間: 2025-3-30 21:33
https://doi.org/10.1007/978-981-13-0496-5Monospecific concepts; Bi-specific constructs; Nanobodies; Immune-oncology; Cancer; Preclinical studies; C作者: mercenary 時間: 2025-3-31 02:43 作者: 和平 時間: 2025-3-31 08:10
